The shift to Polyendocrine Metabolic Ovarian Syndrome (PMOS) reflects a major reclassification after 14 years of global medical consensus.
The global medical establishment has decided to rename Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change was reported this week.
According to The New York Times, the original name PCOS inaccurately suggested that ovarian cysts are a defining feature. The condition often does not involve ovarian cysts and is now understood as both a hormonal and metabolic condition affecting multiple organs.
The renaming process took 14 years and involved over 50 professional medical groups.
PCOS/PMOS affects approximately 170 million women worldwide, or one in eight women.
Background
- PMOS is associated with insulin resistance, Type 2 diabetes, obesity, cardiovascular disease, and obstructive sleep apnea.
- The previous name has been cited as contributing to inadequate clinical training, poorer research funding, delays in diagnosis, and fragmented care.
- PMOS can manifest with varied symptoms; patients may experience different combinations of ovarian cysts, hirsutism, insulin resistance, cystic acne, weight gain, and other issues.
- Common treatments include lifestyle changes, metformin, GLP-1 drugs, myo-inositol, and supplements such as milk thistle, but responses vary individually.